US 11,730,904 B2
Intranasal administration
Per Gisle Djupesland, Oslo (NO); Ramy A. Mahmoud, Yardley, PA (US); Ole A Andreassen, Oslo (NO); Lars T. Westlye, Oslo (NO); Daniel S. Quintana, Oslo (NO); Knut T. Smerud, Oslo (NO); and Colin David Sheldrake, Wiltshire (GB)
Assigned to OptiNose, Inc., Yardley, PA (US)
Filed by OptiNose AS, Oslo (NO)
Filed on Jun. 4, 2021, as Appl. No. 17/338,962.
Application 17/338,962 is a continuation of application No. 14/946,389, filed on Nov. 19, 2015, granted, now 11,052,204.
Claims priority of provisional application 62/081,742, filed on Nov. 19, 2014.
Prior Publication US 2021/0322690 A1, Oct. 21, 2021
Int. Cl. A61M 15/08 (2006.01); A61M 15/00 (2006.01); A61K 38/22 (2006.01); A61K 38/28 (2006.01); A61K 38/095 (2019.01); A61K 38/08 (2019.01); A61K 9/00 (2006.01); A61M 29/00 (2006.01); A61M 11/00 (2006.01); A61M 31/00 (2006.01)
CPC A61M 15/08 (2013.01) [A61K 9/0043 (2013.01); A61K 38/08 (2013.01); A61K 38/095 (2019.01); A61K 38/22 (2013.01); A61K 38/28 (2013.01); A61M 11/00 (2013.01); A61M 15/009 (2013.01); A61M 15/0013 (2014.02); A61M 15/0021 (2014.02); A61M 15/0098 (2014.02); A61M 29/00 (2013.01); A61M 31/00 (2013.01); A61M 2202/04 (2013.01); A61M 2202/064 (2013.01); A61M 2210/0618 (2013.01)] 23 Claims
OG exemplary drawing
 
1. A delivery device for modulating a condition in a human subject, comprising:
a mouthpiece configured to fit within an oral cavity of the subject and permit the subject to exhale therethrough, whereby exhalation by the subject causes closure of an oropharyngeal velum of the subject;
a nosepiece fluidly connected to the mouthpiece and configured to fit within a nostril of the subject, wherein the device is configured to deliver an exhalation breath of the subject from the mouthpiece, through the nosepiece and into a nasal cavity of the subject; and
a delivery pump manually actuatable, on each actuation, to deliver a metered dose of a peptide through the nosepiece to an upper posterior region of the nasal cavity, posterior of a nasal valve of the subject, innervated by the trigeminal nerve, each metered dose containing less than 24 IU.